About US
Contact us
-
New drug significantly lowers bad cholesterolFor many people with high cholesterol, statins serve as the first line of treatment. However, some patients are unable to effectively reduce their low-density lipoprotein cholesterol (LDL cholester2012/11/14
-
Pharma firms choosing to run more phase-IV trialsThere has been an increase in the number of phase-IV clinical trials being initiated voluntarily by pharmaceutical companies, new research shows. Phase-IV trials are sometimes required by regulator2012/11/13
-
Takeda to acquire Envoy TherapeuticsTakeda Pharmaceutical Company's wholly-owned subsidiary, Takeda America Holdings, has entered into a definitive agreement to acquire Envoy Therapeutics and its bacTRAP drug discovery platform. The2012/11/13
-
Hospira returning to market with sedative propofolHospira's ($HSP) inability to provide propofol has been one reason the sedative has been on shortage lists for some time. Now, Hospira says it should be back in the market with a significant supply b2012/11/12
-
CVS shucking more drugs from its coverage listBeginning in January, the list of drugs CVS Caremark's ($CVS) pharmacy-benefit business will refuse to cover will grow to about 50. The company is adding 17 drugs to nearly three dozen it already2012/11/12
-
GSK, XenoPort part ways after Horizant disappointmentGlaxoSmithKline ($GSK) is punting on Horizant. The U.K.-based drugmaker is kicking the restless legs syndrome drug back to partner XenoPort after a series of setbacks, including disappointing sales2012/11/9
-
Sanofi halves the cost of controversial new cancer drug ZaltrapSanofi ($SNY) has put Zaltrap on sale for 50% off. The colorectal cancer drug isn't an overstock, but a brand-new product, approved by FDA in August. Like most new cancer drugs these days, it's expe2012/11/9
-
Obama's re-elected. So what's next for pharma?To call the 2012 election a referendum on Obamacare would be reductionist. But the Affordable Care Act's survival is, no question, the most obvious and specific consequence of President Obama's re-2012/11/8
-
Lundbeck earnings undercut by Lexapro declineDanish drugmaker Lundbeck, whose Lexapro sales have been depressed by generics, managed to maintain a flat operating profit in its third quarter as it works on a potential new blockbuster in hopes2012/11/8
-
Pfizer nabs FDA blessing for blockbuster hopeful XeljanzIt's a banner day for Pfizer ($PFE): The drugmaker's new rheumatoid arthritis drug tofacitinib, one of its leading hopes for sales growth, finally won its approval from the FDA. Now dubbed Xeljanz,2012/11/7